Supriya Lifescience generated more revenue in the September quarter but kept substantially less of it as profit. The pharmaceutical ingredients maker reported standalone revenue of ₹206.30 crore in Q2 FY27, up 3.2% from a year earlier. Net profit fell about 42% to ₹29.25 crore.
Operating profitability also weakened. Company-reported EBITDA fell 37.5% to ₹45.40 crore, and its EBITDA margin narrowed to 22%, from 36.4% a year earlier. That is a decline of roughly 14.4 percentage points.
The Breakdown
Supriya attributed the pressure to three factors: a change in the products and markets generating sales, higher operating expenses at its Ambernath facility, and elevated raw-material and solvent prices.
The company said regulatory changes in Latin America affected demand for some higher-margin products. A greater share of quarterly sales consequently came from semi-regulated markets. For an exporter, the value of growth depends partly on which products sell and where they sell, not just the total billed to customers.
The accounts also show a larger cost base. Other expenditure rose 35.6% to ₹63.69 crore, while depreciation and amortisation increased 42.5% to ₹9.46 crore. Depreciation sits below EBITDA, so the increase adds another layer of pressure between operating earnings and net profit.
The first-half picture shows the same gap between sales and earnings. Revenue increased 14.8% to ₹396.04 crore, while net profit declined 37.5% to ₹53.29 crore.
Production has started. Scale still matters.
Ambernath is already producing commercially, according to the company. Supriya launched two anaesthetic liquid-inhalation products from the facility during the quarter and expects them to scale up over the coming quarters.
Validation and registration batches were also underway, with an EU audit scheduled for November. These are separate milestones: starting production does not mean every intended market is open or that a facility is operating at its eventual sales potential.
A running plant can add expenses before its sales are large enough to spread those costs across more output. Supriya expects better cost absorption as Ambernath’s production and sales increase. The timing and extent of that improvement remain important to its earnings outlook.
The Crunch
Supriya’s next test is how much profit accompanies its growth. A better product mix, progress in market approvals and more sales from Ambernath could help. The September quarter shows why additional revenue alone is an incomplete measure of that progress.
Leave your thoughts